Tandem Diabetes Care logo
Tandem Diabetes Care TNDM
$ 17.72 -4.88%

Annual report 2025
added 02-19-2026

report update icon

Tandem Diabetes Care Balance Sheet 2011-2026 | TNDM

Annual Balance Sheet Tandem Diabetes Care

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

239 M 257 M 243 M 124 M 220 M - -30.8 M -41.8 M 63.3 M 43.1 M 14.6 M 34.4 M -95 M -13 M 4.2 M

Long Term Debt

310 M 308 M 285 M 283 M 281 M - - - 76.5 M 79 M 29.7 M 29.4 M 29.4 M - -

Long Term Debt Current

19.5 M 18.2 M 17.1 M 13.1 M 9.28 M 9.42 M 6.32 M - - - - - - - -

Total Non Current Liabilities

- - - - - - 31.7 M 8.73 M 88.4 M 86.8 M 35.1 M 33.8 M 32.1 M 129 M 68.6 M

Total Current Liabilities

243 M 247 M 195 M 165 M 132 M 104 M 99.4 M 66.3 M 36.1 M 31.5 M 26.5 M 18.1 M - - -

Total Liabilities

726 M 705 M 639 M 613 M 472 M 350 M 131 M 75 M 124 M 118 M 61.7 M 51.9 M 46.7 M 146 M 85.3 M

Deferred Revenue

9.53 M 11.8 M 44 M 18.8 M 10.2 M 6.08 M 3.87 M 4.6 M 2.53 M 5.21 M 1.82 M 840 K 411 K 1.88 M -

Retained Earnings

-1.25 B -1.05 B -952 M -729 M -635 M - -625 M -600 M -478 M -405 M -321 M -249 M -169 M -106 M -72.7 M

Total Assets

881 M 968 M 953 M 1.05 B 905 M 716 M 326 M 206 M 95.3 M 112 M 125 M 106 M 162 M 39.8 M 14 M

Cash and Cash Equivalents

90.6 M 69.2 M 58.9 M 173 M 71.2 M 94.6 M 51.2 M 41.8 M 13.7 M 44.7 M 43.1 M 31.2 M 124 M 17.2 M -

Book Value

155 M 263 M 314 M 440 M 433 M 366 M 195 M 131 M -29.1 M -5.93 M 63.5 M 54.6 M 116 M -106 M -71.3 M

Total Shareholders Equity

155 M 263 M 314 M 440 M 433 M 366 M 195 M 131 M -29.1 M -5.93 M 63.5 M 54.6 M 116 M -106 M -

All numbers in USD currency

Quarterly Balance Sheet Tandem Diabetes Care

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

310 M 309 M 309 M 308 M 308 M 307 M 347 M 285 M 285 M 284 M 284 M 283 M 283 M - 282 M 281 M 281 M 281 M 280 M 203 M 203 M 203 M 203 M - - - 10.7 M - - - - 82.7 M - - 82.7 M 81.1 M - - - 30.2 M 30 M 30 M 30 M 30 M 30 M 30 M 30 M - - - - - - - - - - - -

Total Liabilities

742 M 742 M 767 M 705 M 720 M 704 M 698 M 639 M 626 M 617 M 615 M 613 M 626 M - 578 M 472 M 461 M 449 M 441 M 350 M 350 M 350 M 350 M 131 M 131 M 131 M 93.7 M 75 M 75 M 75 M 75 M 124 M 124 M 124 M 124 M 118 M 118 M 118 M 118 M 61.3 M 61.3 M 61.3 M 61.3 M 51.9 M 51.9 M 51.9 M 51.9 M 46.7 M 46.7 M 46.7 M 46.7 M - - - - - - - -

Deferred Revenue

9.84 M 10.5 M 11 M 11.8 M 42.6 M 44.2 M 44.6 M 44 M 31.6 M 23.4 M 20.8 M 18.8 M 13 M - 10.9 M 10.2 M 9.02 M 7.95 M 6.67 M 6.08 M 6.08 M 6.08 M 6.08 M 3.87 M 3.87 M 3.87 M 5.46 M 4.6 M 4.6 M 4.6 M 4.6 M 2.53 M 2.53 M 2.53 M 2.53 M 5.21 M 5.21 M 5.21 M 5.21 M 1.82 M 1.82 M 1.82 M 1.82 M 840 K 840 K 840 K 840 K 411 K 411 K 411 K 411 K - - - - - - - -

Retained Earnings

-1.25 B -1.23 B -1.18 B -1.05 B -1.05 B -1.03 B -995 M -952 M -922 M -889 M -853 M -729 M -713 M - -649 M -635 M -645 M -651 M -655 M -659 M -659 M -659 M -659 M -625 M -625 M -625 M -623 M -600 M -600 M -600 M -600 M -478 M -478 M -478 M -478 M -405 M -405 M -405 M -405 M -321 M -321 M -321 M -321 M -249 M -249 M -249 M -249 M -169 M -169 M -169 M -169 M - - - - - - - -

Total Assets

875 M 876 M 922 M 968 M 958 M 938 M 941 M 953 M 940 M 947 M 954 M 1.05 B 1.05 B - 1.02 B 905 M 850 M 795 M 754 M 716 M 716 M 716 M 716 M 326 M 326 M 326 M 215 M 206 M 206 M 206 M 206 M 95.3 M 95.3 M 95.3 M 95.3 M 112 M 112 M 112 M 112 M 125 M 125 M 125 M 125 M 106 M 106 M 106 M 106 M 162 M 162 M 162 M 162 M - - - - - - - -

Cash and Cash Equivalents

91.9 M 64.1 M 53.6 M 69.2 M 49 M 47.7 M 59 M 58.9 M 79.6 M 131 M 128 M 173 M 124 M 115 M 93.7 M 71.2 M 112 M 98.6 M 121 M 94.6 M 94.6 M 94.6 M 94.6 M 51.2 M 51.2 M 51.2 M 40.4 M 41.8 M 41.8 M 41.8 M 41.8 M 13.7 M 13.7 M 13.7 M 13.7 M 44.7 M 44.7 M 44.7 M 44.7 M 43.1 M 43.1 M 43.1 M 43.1 M 31.2 M 31.2 M 31.2 M 31.2 M 124 M 124 M 124 M 124 M 17.2 M - - - 8.66 M - - -

Book Value

133 M 133 M 155 M 263 M 238 M 234 M 243 M 314 M 314 M 329 M 339 M 440 M 422 M - 437 M 433 M 390 M 346 M 313 M 366 M 366 M 366 M 366 M 195 M 195 M 195 M 121 M 131 M 131 M 131 M 131 M -29.1 M -29.1 M -29.1 M -29.1 M -5.93 M -5.93 M -5.93 M -5.93 M 63.5 M 63.5 M 63.5 M 63.5 M 54.6 M 54.6 M 54.6 M 54.6 M 116 M 116 M 116 M 116 M - - - - - - - -

Total Shareholders Equity

133 M 133 M 155 M 263 M 238 M 234 M 243 M 314 M 314 M 329 M 339 M 440 M 422 M 450 M 437 M 433 M 390 M 346 M 313 M 366 M 366 M 366 M 366 M 195 M 195 M 195 M 121 M 131 M 131 M 131 M 131 M -29.1 M -29.1 M -29.1 M -29.1 M -5.93 M -5.93 M -5.93 M -5.93 M 63.5 M 63.5 M 63.5 M 63.5 M 54.6 M 54.6 M 54.6 M 54.6 M 116 M 116 M 116 M 116 M -106 M - - - -71.3 M - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Tandem Diabetes Care, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Medical devices

Issuer Price % 24h Market Cap Country
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
Electromed Electromed
ELMD
$ 25.34 -2.61 % $ 214 M usaUSA
AdaptHealth Corp. AdaptHealth Corp.
AHCO
$ 12.98 -2.99 % $ 1.75 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
$ 3.3 -0.15 % $ 124 M franceFrance
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Helius Medical Technologies Helius Medical Technologies
HSDT
$ 1.97 -5.28 % $ 1.2 M usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
$ 0.64 7.43 % $ 39.8 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 10.17 -8.21 % $ 288 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Globus Medical Globus Medical
GMED
$ 88.1 -2.88 % $ 11.9 B usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
GBS GBS
GBS
- -0.57 % $ 7.12 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
$ 1.2 -2.45 % $ 48.8 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Orthofix Medical Orthofix Medical
OFIX
$ 11.47 -3.69 % $ 454 M curacaoCuracao
Butterfly Network Butterfly Network
BFLY
$ 4.89 -5.15 % $ 1.04 B usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
Insulet Corporation Insulet Corporation
PODD
$ 162.26 -11.27 % $ 11.4 B usaUSA
OrthoPediatrics Corp. OrthoPediatrics Corp.
KIDS
$ 14.66 -3.2 % $ 344 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 10.15 -3.79 % $ 364 M usaUSA
IRIDEX Corporation IRIDEX Corporation
IRIX
$ 1.03 -0.96 % $ 17.4 M usaUSA
Sintx Technologies Sintx Technologies
SINT
$ 2.01 -6.74 % $ 5.57 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 35.42 -3.71 % $ 1.1 B usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 59.11 -3.56 % $ 3.22 B britainBritain
Inspire Medical Systems Inspire Medical Systems
INSP
$ 52.89 -4.0 % $ 1.55 B usaUSA
LENSAR LENSAR
LNSR
$ 5.33 -0.47 % $ 63.7 M usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 83.35 -1.57 % $ 2.9 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
EW
$ 81.31 -1.18 % $ 47.6 B usaUSA
TELA Bio TELA Bio
TELA
$ 0.83 6.01 % $ 39 M usaUSA
Tactile Systems Technology Tactile Systems Technology
TCMD
$ 22.41 -4.92 % $ 513 M usaUSA
Stryker Corporation Stryker Corporation
SYK
$ 312.54 -2.78 % $ 119 B usaUSA